Revisiting "BAP1ness" in Malignant Pleural Mesothelioma

Affiliations

¹ Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China. Electronic address: yanghaitang@shchest.org.
² Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
³ Division of General Thoracic Surgery, Department of BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Free article

Comment

Haitang Yang et al. J Thorac Oncol. 2022 Aug.

Free article

. 2022 Aug;17(8):e67-e69.

doi: 10.1016/j.jtho.2022.04.014.

¹ Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China. Electronic address: yanghaitang@shchest.org.
² Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
³ Division of General Thoracic Surgery, Department of BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

No abstract available

Comment in

Response to "Revisiting 'BAP1ness' in Malignant Pleural Mesothelioma".
Røe OD, Creaney J; BAP1 Study Group. Røe OD, et al. J Thorac Oncol. 2022 Aug;17(8):e69-e70. doi: 10.1016/j.jtho.2022.05.013. J Thorac Oncol. 2022. PMID: 35931425 No abstract available.

BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
Louw A, Panou V, Szejniuk WM, Meristoudis C, Chai SM, van Vliet C, Lee YCG, Dick IM, Firth T, Lynggaard LA, Asghari AB, Vyberg M, Hansen J, Creaney J, Røe OD. Louw A, et al. J Thorac Oncol. 2022 Jul;17(7):921-930. doi: 10.1016/j.jtho.2022.04.008. Epub 2022 Apr 27. J Thorac Oncol. 2022. PMID: 35489694